贝伐单抗
医学
表阿霉素
多西紫杉醇
化疗
紫杉烷
内科学
环磷酰胺
乳腺癌
肿瘤科
蒽环类
优势比
卡培他滨
癌症
结直肠癌
作者
Bernhard Gerber,Sibylle Loibl,Holger Eidtmann,Mahdi Rezai,Peter Andreas Fasching,Hans Tesch,Holm Eggemann,Iris Schrader,Kornelia Kittel,Claus Alexander Hanusch,R. Kreienberg,Christine Solbach,Christian Jackisch,Georg Kunz,Jens‐Uwe Blohmer,Jens Huober,Maik Hauschild,Valentina Nekljudova,Michael Untch,Gϋnter von Minckwitz
标识
DOI:10.1093/annonc/mdt361
摘要
BackgroundWe evaluated the pathological complete response (pCR) rate after neoadjuvant epirubicin, (E) cyclophosphamide (C) and docetaxel containing chemotherapy with and without the addition of bevacizumab in patients with triple-negative breast cancer (TNBC).Patients and methodsPatients with untreated cT1c-4d TNBC represented a stratified subset of the 1948 participants of the HER2-negative part of the GeparQuinto trial. Patients were randomized to receive four cycles EC (90/600 mg/m2; q3w) followed by four cycles docetaxel (100 mg/m2; q3w) each with or without bevacizumab (15 mg/kg; q3w) added to chemotherapy.ResultsTNBC patients were randomized to chemotherapy without (n = 340) or with bevacizumab (n = 323). pCR (ypT0 ypN0, primary end point) rates were 27.9% without and 39.3% with bevacizumab (P = 0.003). According to other pCR definitions, the addition of bevacizumab increased the pCR rate from 30.9% to 41.8% (ypT0 ypN0/+; P = 0.004), 36.2% to 46.4% (ypT0/is ypN0/+; P = 0.009) and 32.9% to 43.3% (ypT0/is ypN0; P = 0.007). Bevacizumab treatment [OR 1.73, 95% confidence interval (CI) 1.23–2.42; P = 0.002], lower tumor stage (OR 2.38, 95% CI 1.24–4.54; P = 0.009) and grade 3 tumors (OR 1.68, 95% CI 1.14–2.48; P = 0.009) were confirmed as independent predictors of higher pCR in multivariate logistic regression analysis.ConclusionsThe addition of bevacizumab to chemotherapy in TNBC significantly increases pCR rates.
科研通智能强力驱动
Strongly Powered by AbleSci AI